Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
0.45
Industry P/E
--
Debt to Equity
-0
ROE
-5.71 %
ROCE
0.38 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-37.04 Mln
EBITDA
$-47.56 Mln
Net Profit
$-97.65 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Petros Pharmaceuticals (PTPI)
| -86.29 | -23.94 | -83.54 | -91.49 | -84.16 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Petros Pharmaceuticals (PTPI)
| -71.77 | -39.48 | -93.00 | -24.32 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the... commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036 Read more
Executive Chairman of the Board
Mr. John David Shulman
Executive Chairman of the Board
Mr. John David Shulman
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Petros Pharmaceuticals Inc (PTPI) stood at $ 10,635 Mln as on 31-Dec-24
The share price of Petros Pharmaceuticals Inc (PTPI) is $0.05 (NASDAQ) as of 25-Apr-2025 16:22 EDT. Petros Pharmaceuticals Inc (PTPI) has given a return of -84.16% in the last 3 years.
Petros Pharmaceuticals Inc (PTPI) has a market capitalisation of $ 2 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Petros Pharmaceuticals Inc (PTPI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Petros Pharmaceuticals Inc (PTPI) and enter the required number of quantities and click on buy to purchase the shares of Petros Pharmaceuticals Inc (PTPI).
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
The CEO & director of Mr. John David Shulman. is Petros Pharmaceuticals Inc (PTPI), and CFO & Sr. VP is Mr. John David Shulman.
There is no promoter pledging in Petros Pharmaceuticals Inc (PTPI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Petros Pharmaceuticals Inc. (PTPI) | Ratios |
|---|---|
|
Return on equity(%)
|
0.38
|
|
Operating margin(%)
|
-291.07
|
|
Net Margin(%)
|
-0.28
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Petros Pharmaceuticals Inc (PTPI) was $0 Mln.
$0.00
(
